{"id":20351,"date":"2022-12-20T18:07:10","date_gmt":"2022-12-20T12:37:10","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=20351"},"modified":"2022-12-20T18:09:23","modified_gmt":"2022-12-20T12:39:23","slug":"pharma-news-for-abbvie-ferring-merck-csl","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-abbvie-ferring-merck-csl","title":{"rendered":"Fourth FDA Approval for AbbVie\u2019s Vraylar; FDA Approves Ferring\u2019s Adstiladrin for NMIBC; Merck and Moderna\u2019s mRNA Cancer Vaccine Trial; EMA Recommends the CSL\u2019s Gene Therapy for Hemophilia B; CHMP Backs Amicus\u2019 Pompe Disease Therapy; Takeda Announces the Phase 3 AURORA Study Result"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a03b3260603f\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a03b3260603f\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-abbvie-ferring-merck-csl\/#AbbVie_Secures_Fourth_FDA_Approval_for_Vraylar\" >AbbVie Secures Fourth FDA Approval for Vraylar<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-abbvie-ferring-merck-csl\/#FDA_Approves_Ferring_Pharmaceuticals_Adstiladrin_as_First_Gene_Therapy_for_NMIBC\" >FDA Approves Ferring Pharmaceuticals\u2019 Adstiladrin as First Gene Therapy for NMIBC<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-abbvie-ferring-merck-csl\/#CSLs_Gene_Therapy_for_Hemophilia_B_Recommends_for_approval_by_the_EMAs_Human_Medicine_Committee\" >CSL\u2019s Gene Therapy for Hemophilia B Recommends for approval by the EMA\u2019s Human Medicine Committee<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-abbvie-ferring-merck-csl\/#Merck_and_Modernas_mRNA_Cancer_Vaccine_Aces_its_First_Efficacy_Trial\" >Merck and Moderna\u2019s mRNA Cancer Vaccine Aces its First Efficacy Trial<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-abbvie-ferring-merck-csl\/#Takeda_Announces_the_Phase_3_AURORA_Study_Result_of_Maribavir\" >Takeda Announces the Phase 3 AURORA Study Result of Maribavir&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-abbvie-ferring-merck-csl\/#CHMP_Backs_Amicus_Therapy_for_Pompe_Disease\" >CHMP Backs Amicus\u2019 Therapy for Pompe Disease<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-abbvie-secures-fourth-fda-approval-for-vraylar\"><span class=\"ez-toc-section\" id=\"AbbVie_Secures_Fourth_FDA_Approval_for_Vraylar\"><\/span><strong>AbbVie Secures Fourth FDA Approval for Vraylar<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>AbbVie <\/strong>has received its fourth FDA approval for <strong>Vraylar<\/strong>, adding major depressive disorder (MDD) adjunctive therapy to a list that includes schizophrenia and manic and depressive episodes in bipolar disorder. According to <strong>AbbVie<\/strong>, the approval makes <a href=\"https:\/\/www.delveinsight.com\/report-store\/vralyar-emerging-drug-insight-and-market-forecast\"><strong>Vraylar (cariprazine)<\/strong><\/a> the &#8220;first and only&#8221; dopamine and serotonin partial agonist indicated as an add-on therapy for depression, adding to the growing list of options for patients who struggle to control their mood with standard antidepressants alone.<\/p>\n\n\n\n<p>The term &#8220;responsibility&#8221; refers to the act of determining whether or not a person is responsible for the actions of another person. Following a sluggish start, the drug has emerged as the star of AbbVie&#8217;s <strong>USD 63 billion<\/strong> mega-merger with Allergan, which developed the drug with AbbVie.<\/p>\n\n\n\n<p>Despite mixed results in clinical trials of the drug as an <a href=\"https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-market\">adjunctive treatment for depression<\/a>, the FDA made its decision. It follows a new pair of pivotal trials <strong>(RGH-MD-75 and 3111-301-001)<\/strong> that found a clinically and statistically significant change from baseline on Montgomery-sberg Depression Rating Scale (MADRS) scores compared to placebo when a once-daily dose of Vraylar was added to background therapy &#8211; within a few weeks.<\/p>\n\n\n\n<p>There is still a pressing need for antidepressant therapies that can begin to work faster than current tricyclic or selective serotonin reuptake inhibitor drugs, which can take weeks to work, putting severely affected patients at risk of self-harm before they kick in. In another late-stage trial, Vraylar was unable to improve depressive symptoms from baseline to week six in the MADRS total score when compared to placebo <strong>(3111-302-001)<\/strong>. Meanwhile, in the <strong>3111-301-001<\/strong> study, Vraylar exerted its benefit at a lower dose (1.5 mg\/day) but not at a Higher dose (3.0 mg\/kg), undermining the top-line finding.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_Approves_Ferring_Pharmaceuticals_Adstiladrin_as_First_Gene_Therapy_for_NMIBC\"><\/span><strong>FDA Approves Ferring Pharmaceuticals\u2019 Adstiladrin as First Gene Therapy for NMIBC<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The US Food and Drug Administration (FDA) has approved Swiss drugmaker <strong>Ferring Pharmaceuticals&#8217; Adstiladrin (nadofaragene firedenovec-vncg)<\/strong> for the treatment of adult patients with high-risk Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.<\/p>\n\n\n\n<p>Bladder cancer is a relatively common type of cancer. According to the Centers for Disease Control and Prevention, approximately <strong>57,000<\/strong> men and <strong>8,000<\/strong> women are diagnosed with bladder cancer each year, and approximately <strong>12,000<\/strong> men and <strong>4,700<\/strong> women die from the disease.<\/p>\n\n\n\n<p><strong>Adstiladrin<\/strong>, developed by <strong>Ferring Pharma<\/strong>, is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy. Its safety and efficacy were assessed in a multi-center clinical study of <strong>157 patients<\/strong> with high-risk BCG-unresponsive NMIBC, <strong>98<\/strong> of whom had BCG-unresponsive CIS with or without papillary tumors. Adstiladrin was administered into the bladder via a urinary catheter once every three months for up to 12 months or until unacceptable toxicity to therapy or recurrent high-grade NMIBC. Individuals who are immunosuppressed or immune-deficient should not come into contact with Adstiladrin.<\/p>\n\n\n\n<p>Priority Review, Breakthrough Therapy, and Fast Track designations were given to the application. The FDA approval makes <strong>Adstiladrin <\/strong>the first gene therapy to be approved for adult <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-muscle-invasive-bladder-cancer-market\">patients with high-risk BCG-unresponsive NMIBC<\/a> with CIS. Ferring intends to make the drug economically accessible to patients, and it is scheduled to become commercially available in the United States in the second half of 2023.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"CSLs_Gene_Therapy_for_Hemophilia_B_Recommends_for_approval_by_the_EMAs_Human_Medicine_Committee\"><\/span><strong>CSL\u2019s Gene Therapy for Hemophilia B Recommends for approval by the EMA\u2019s Human Medicine Committee<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The first FDA-approved gene therapy for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-pipeline-insight\"><strong>treatment of the genetic bleeding disorder hemophilia B<\/strong><\/a>, CSL&#8217;s Hemgenix (etranacogene dezaparvovec), received a conditional marketing authorization recommendation on Friday from the European Medicines Agency.<\/p>\n\n\n\n<p>Hemogenix is working to lessen the need for the lifetime intravenous infusions of <a href=\"https:\/\/www.delveinsight.com\/report-store\/factor-xi-inhibitors-pipeline-insight\">factor IX<\/a> replacement medications that hemophilia B patients now need to maintain adequate factor IX levels. The EMA&#8217;s recommendation is based on the findings of two open-label, single-dose, single-arm studies in which 55\/57 adult male <a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-epidemiology-forecast\"><strong>patients with moderately severe or severe hemophilia B<\/strong><\/a> sustained positive treatment effects for at least two years, despite the fact that the long-term durability of the therapy is unknown.<\/p>\n\n\n\n<p>Following the FDA&#8217;s approval of the $3.5 million in cost gene treatment last month, CSL Behring gained notoriety. When it is approved, the price in Europe won&#8217;t be disclosed by the corporation.<\/p>\n\n\n\n<p>Analysts at Wall Street firm SVB Leerink said Friday they estimate an EU price of $2.5 million, adding, we expect to learn more about the patient uptake trajectory as Hemgenix launches in the US and EU in 2023, but we see a compelling commercial opportunity ahead, even with limited uptake. Our model currently assumes that Hemgenix will achieve peak penetration of 5% in the moderate HemB population and 15% in the severe HemB population in both the US and EU, and we currently model peak (2030E) non-risk-adj. global sales of $2.4bn for Hemgenix.<\/p>\n\n\n\n<p>The biotech company presented six months&#8217; worth of durability data at ASH last week, demonstrating the continued efficacy of their medication.<\/p>\n\n\n\n<p>All but three of the 54 <a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-pipeline-insight\"><strong>hemophilia B patients treated with gene therapy<\/strong><\/a>, according to the company, were able to stop using prophylactic medication and avoided needing it for 18 months. The corporation claimed that the efficacy hadn&#8217;t changed even after six more months of data.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Merck_and_Modernas_mRNA_Cancer_Vaccine_Aces_its_First_Efficacy_Trial\"><\/span><strong>Merck and Moderna\u2019s mRNA Cancer Vaccine Aces its First Efficacy Trial<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>According to Merck &amp; Co. and Moderna, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/global-messenger-rna-mrna-based-vaccines-and-therapeutics-market\"><strong>mRNA technology<\/strong><\/a> that was used so successfully in vaccines against <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-coronavirus-pipeline-insights\">COVID-19<\/a> has now been discovered to hold similar promise against cancer. The two partners have released the first clinical data from a phase 2b trial of a personalized vaccine made up of 34 mRNAs, each of which targets mutations considered to be responsible for a patient&#8217;s cancer and were discovered by gene sequencing.<\/p>\n\n\n\n<p>In the experiment,<strong> <\/strong>individuals with skin cancer melanoma were given either Keytruda (pembrolizumab) alone or Moderna&#8217;s MRNA-4157\/V940 vaccination in addition to Merck &amp; Co.&#8217;s cancer treatment Keytruda (pembrolizumab). Comparing the combination to the standard of care for individuals with this kind of cancer, Keytruda alone, the risk of death or disease progression was decreased by 44%. Because of its high concentration of white blood cells and reputation as a &#8220;hot&#8221; tumor that responds to immunotherapies, melanoma was selected for the experiment. While Keytruda disables an immune &#8220;brake&#8221; shielding cancer, the vaccine primes the immune system to attack tumor cells.&nbsp;<\/p>\n\n\n\n<p>\u201cThese data provide the first evidence that we can improve on the rates of recurrence-free survival achieved by <a href=\"https:\/\/www.delveinsight.com\/report-store\/pd-1-and-pd-l1-inhibitors-competitive-landscape\"><strong>PD-1 blockade in resected high-risk melanoma<\/strong><\/a>,\u201d said Jeffrey Weber, principal investigator in the trial. The results, he continued, also offer the first randomized proof that a tailored, &#8220;neoantigen&#8221; vaccine approach may be helpful in the treatment of cancer. The main challenge the partners must overcome is scaling up the individual manufacturing technique to make it an attractive, practical choice for health systems.<\/p>\n\n\n\n<p>Currently, it takes more than eight weeks, from a biopsy to the collection of cells for sequencing to the administration of the customized shot, while efforts are being made to cut that time in half to around a month. At the population level, however, access to sequencing might be a significant barrier.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Takeda_Announces_the_Phase_3_AURORA_Study_Result_of_Maribavir\"><\/span><strong>Takeda Announces the Phase 3 AURORA Study Result of Maribavir&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On December 19, 2022, Takeda announced that in the AURORA trial, a Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/cytomegalovirus-cmv-infection-market\"><strong>treatment of CMV infection<\/strong><\/a> in <a href=\"https:\/\/www.delveinsight.com\/report-store\/hematopoietic-stem-cell-transplantation-market\"><strong>hematopoietic stem cell transplant (HSCT) recipients<\/strong><\/a>. Takeda has further updated that maribavir demonstrated clinically meaningful efficacy in confirmed CMV viremia clearance, but did not meet its primary endpoint of non-inferiority vs. valganciclovir.&nbsp;<\/p>\n\n\n\n<p>CMV is a beta herpesvirus that commonly infects humans; serologic evidence of prior infection can be found in 40-100% of various adult populations. Takeda\u2019s LIVTENCITY, an orally bioavailable anti-CMV compound, is the first and only antiviral agent that targets and inhibits the UL97 protein kinase and its natural substrates. The therapy is approved by the US FDA for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/cytomegalovirus-cmv-infection-epidemiology-forecast\"><strong>adults and pediatric patients with post-transplant CMV infection\/disease<\/strong><\/a> that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet. Moreover, the Takeda is set to share the AURORA study results with relevant regulatory agencies and will continue to engage with them on a potential path forward for maribavir in asymptomatic first-episode post-transplant CMV infection. Furthermore, the AURORA study results will also be submitted for publication in a peer-reviewed journal.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"CHMP_Backs_Amicus_Therapy_for_Pompe_Disease\"><\/span><strong>CHMP Backs Amicus\u2019 Therapy for Pompe Disease<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On on December 16, 2022, according to Amicus Therapeutics (LOPD) has announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a favorable opinion and recommended marketing authorization of cipaglucosidase alfa, a long-term enzyme replacement therapy (ERT) used in combination with miglustat for <a href=\"https:\/\/www.delveinsight.com\/report-store\/pompe-disease-epidemiology-forecast\"><strong>adults with late-onset Pompe disease<\/strong><\/a>. Additionally, the CHMP opinion on miglustat, the enzyme stabiliser component of AT-GAA, is anticipated in the second quarter of 2023.&nbsp;<\/p>\n\n\n\n<p>AT-GAA is designed as a two-component therapy consisting of cipaglucosidase alfa, a long-term enzyme replacement therapy, administered in combination with miglustat, an oral enzyme stabiliser, for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/pompe-disease-pipeline-insight\"><strong>treatment of adults with late-onset Pompe disease<\/strong><\/a>. The CHMP&#8217;s decision was based on the encouraging clinical data from the Phase 3 pivotal research (PROPEL), which is a randomized, controlled trial in LOPD to include patients in the high unmet need ERT-experienced population, in addition to ERT-na\u00efve patients. As anticipated and consistent with a recent opinion of another ERT in this disease space, the CHMP also determined cipaglucosidase alfa does not qualify as a New Active Substance (NAS).&nbsp;<\/p>\n\n\n\n<p>John F. Crowley, Executive Chairman and Founder of Amicus Therapeutics, Inc. has said, \u201cToday\u2019s positive CHMP opinion for Pombiliti&#x2122; (cipaglucosidase alfa) is a significant milestone and major step towards bringing this much needed new treatment for all adults living in the EU with late-onset Pompe disease. It is the realization of the work of so many individuals and teams dedicated to the mission of improving the lives of people living with Pompe disease\u201d.<\/p>\n\n\n\n<p>The European Commission (EC) is expected to take the decision on cipaglucosidase alfa, the enzyme replacement therapy component of AT-GAA, in the first quarter of 2023. Late-onset Pompe disease is a rare, debilitating, and life-threatening lysosomal disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced or absent levels of GAA lead to the accumulation of the substrate glycogen in the lysosomes of muscles and other tissues. Cipaglucosidase alfa is a recombinant human acid alpha-glucosidase enzyme (rhGAA) enriched with bis-mannose-6-phosphate designed to facilitate high-affinity uptake with retained capacity for processing into the most active form of the enzyme to break down glycogen.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie Secures Fourth FDA Approval for Vraylar AbbVie has received its fourth FDA approval for Vraylar, adding major depressive disorder (MDD) adjunctive therapy to a list that includes schizophrenia and manic and depressive episodes in bipolar disorder. According to AbbVie, the approval makes Vraylar (cariprazine) the &#8220;first and only&#8221; dopamine and serotonin partial agonist indicated [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":20354,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[7335,704,258,285,349,394,19178,420,20061,16712,639,489],"industry":[17225],"therapeutic_areas":[17238,17233,17231,17245,17228],"class_list":["post-20351","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-bipolar-disorder","tag-fda","tag-gene-therapy","tag-hemophilia-b","tag-latest-pharma-news","tag-melanoma","tag-mrna-vaccine","tag-news","tag-nmibc","tag-nmibc-market","tag-pharma-news","tag-pompe-disease","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-hematological-disorders","therapeutic_areas-infectious-diseases","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News and Updates | AbbVie, Ferring, Merck, CSL, Amicus, Takeda<\/title>\n<meta name=\"description\" content=\"AbbVie\u2019s Vraylar; Ferring\u2019s Adstiladrin; Merck and Moderna\u2019s mRNA Cancer Vaccine; CSL\u2019s Gene Therapy for Hemophilia B; Amicus\u2019 Pompe Disease\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-abbvie-ferring-merck-csl\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News and Updates | AbbVie, Ferring, Merck, CSL, Amicus, Takeda\" \/>\n<meta property=\"og:description\" content=\"AbbVie\u2019s Vraylar; Ferring\u2019s Adstiladrin; Merck and Moderna\u2019s mRNA Cancer Vaccine; CSL\u2019s Gene Therapy for Hemophilia B; Amicus\u2019 Pompe Disease\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-abbvie-ferring-merck-csl\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-20T12:37:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-12-20T12:39:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/20180344\/Pharma-News-and-Updates-for-AbbVie-Ferring-Merck-CSL-Amicus-Takeda.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News and Updates | AbbVie, Ferring, Merck, CSL, Amicus, Takeda","description":"AbbVie\u2019s Vraylar; Ferring\u2019s Adstiladrin; Merck and Moderna\u2019s mRNA Cancer Vaccine; CSL\u2019s Gene Therapy for Hemophilia B; Amicus\u2019 Pompe Disease","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-abbvie-ferring-merck-csl","og_locale":"en_US","og_type":"article","og_title":"Pharma News and Updates | AbbVie, Ferring, Merck, CSL, Amicus, Takeda","og_description":"AbbVie\u2019s Vraylar; Ferring\u2019s Adstiladrin; Merck and Moderna\u2019s mRNA Cancer Vaccine; CSL\u2019s Gene Therapy for Hemophilia B; Amicus\u2019 Pompe Disease","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-abbvie-ferring-merck-csl","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-12-20T12:37:10+00:00","article_modified_time":"2022-12-20T12:39:23+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/20180344\/Pharma-News-and-Updates-for-AbbVie-Ferring-Merck-CSL-Amicus-Takeda.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-abbvie-ferring-merck-csl","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-abbvie-ferring-merck-csl","name":"Pharma News and Updates | AbbVie, Ferring, Merck, CSL, Amicus, Takeda","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-abbvie-ferring-merck-csl#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-abbvie-ferring-merck-csl#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/20180344\/Pharma-News-and-Updates-for-AbbVie-Ferring-Merck-CSL-Amicus-Takeda.png","datePublished":"2022-12-20T12:37:10+00:00","dateModified":"2022-12-20T12:39:23+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"AbbVie\u2019s Vraylar; Ferring\u2019s Adstiladrin; Merck and Moderna\u2019s mRNA Cancer Vaccine; CSL\u2019s Gene Therapy for Hemophilia B; Amicus\u2019 Pompe Disease","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-abbvie-ferring-merck-csl"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-abbvie-ferring-merck-csl#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/20180344\/Pharma-News-and-Updates-for-AbbVie-Ferring-Merck-CSL-Amicus-Takeda.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/20180344\/Pharma-News-and-Updates-for-AbbVie-Ferring-Merck-CSL-Amicus-Takeda.png","width":772,"height":482,"caption":"Pharma News and Updates for AbbVie, Ferring, Merck, CSL, Amicus, Takeda"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/20180344\/Pharma-News-and-Updates-for-AbbVie-Ferring-Merck-CSL-Amicus-Takeda-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bipolar disorder<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">hemophilia B<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">melanoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">mRNA vaccine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NMIBC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NMIBC Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pompe Disease<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Bipolar disorder<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">hemophilia B<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">melanoma<\/span>","<span class=\"advgb-post-tax-term\">mRNA vaccine<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">NMIBC<\/span>","<span class=\"advgb-post-tax-term\">NMIBC Market<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Pompe Disease<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Dec 20, 2022","modified":"Updated on Dec 20, 2022"},"absolute_dates_time":{"created":"Posted on Dec 20, 2022 6:07 pm","modified":"Updated on Dec 20, 2022 6:09 pm"},"featured_img_caption":"Pharma News and Updates for AbbVie, Ferring, Merck, CSL, Amicus, Takeda","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/20351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=20351"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/20351\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/20354"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=20351"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=20351"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=20351"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=20351"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=20351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}